Oramed’s Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment

NEW YORK, Sept. 15, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled over 50% of patients planned for its Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis […]

Join our mailing list

Skip to content